{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-001468","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2026-09-09T14:12:04+00:00","discovered_at":"2026-09-09T14:13:00.377358+00:00","generated_at":"2026-09-09T14:13:05.167602+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria raises ~$5.9M via warrant exercise at $12.92/share; issues new warrants","bullets":["453,969 existing warrants exercised at reduced $12.92/share, gross proceeds ~$5.9M before fees.","New Series A warrants (5-yr, $12.67) and Series B warrants (18-mo, $12.67) issued for 453,969 shares each.","H.C. Wainwright acts as placement agent; fee 7% of gross proceeds plus 15,889 agent warrants at $16.15.","CEO cites $2.6M Australian Tax Office rebate received; proceeds to fund 2027 operations and R&D.","Closing expected Sept 9, 2026; resale registration statement to be filed within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-001468","json":"https://secwatch.observer/filing/0001640334-26-001468.json","markdown":"https://secwatch.observer/filing/0001640334-26-001468.md","text":"https://secwatch.observer/filing/0001640334-26-001468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/0001640334-26-001468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T14:13:05.167602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}